[1] Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet, 2015, 386:1546-1555. [2] Lo GH. The use of transjugular intrahepatic portosystemic stent shunt (TIPS) in the management of portal hypertensive bleeding. J Chin Med Assoc, 2014, 77:395-402. [3] Villanueva C, Albillos A, Genescà J, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 2019, 393:1597-1608. [4] 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版).中华肝脏病杂志, 2019, 27:938-961. [5] Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology, 2017, 65: 310-335. [6] Cifuentes LI, Gattini D, Torres-Robles R, et al. Beta-blockers versus placebo or no intervention for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis. Cochrane Database Syst Rev, 2021, 1:CD011973. [7] Qi X, Berzigotti A, Cardenas A, et al. Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension. Lancet Gastroenterol Hepatol, 2018, 3:708-719. [8] Hoffman DH, Ayoola A, Nickel D, et al. MR elastography, T1 and T2 relaxometry of liver: role in noninvasive assessment of liver function and portal hypertension. Abdom Radiol (NY), 2020, 45:2680-2687. [9] Guillaume M, Bureau C. Should the presence of spontaneous portosystemic shunts be implemented to the model for end-stage liver disease score for a better prediction of outcome. Gastroenterology, 2018, 154:1569-1571. [10] Gouya H, Grabar S, Vignaux O, et al. Portal hypertension in patients with cirrhosis: indirect assessment of hepatic venous pressure gradient by measuring azygos flow with 2D-cine phase-contrast magnetic resonance imaging. Eur Radiol, 2016, 26:1981-1990. [11] Lin JY, Zhang CH, Zheng L, et al. Establishment and assessment of the hepatic venous pressure gradient using biofluid mechanics (HVPGBFM): protocol for a prospective, randomised, non-controlled, multicentre study. BMJ Open, 2019, 9:e028518. [12] Leng X, Zhang F, Zhang M, et al. Comparison of transjugular intrahepatic portosystemic shunt for treatment of variceal bleeding in patients with cirrhosis with or without spontaneous portosystemic shunt. Eur J Gastroenterol Hepatol, 2019, 31:853-858. [13] Li LN, Sun XY, Wang GC, et al. Transjugular intrahepatic portosystemic shunt prevents rebleeding in cirrhotic patients having cavernous transformation of the portal vein without improving their survival. J Dig Dis, 2019, 20:89-96. [14] Li ZP, Wang SS, Wang GC, et al. Transjugular intrahepatic portosystemic shunt for the prevention of recurrent esophageal variceal bleeding in patients with cavernous transformation of portal vein. Hepatobiliary Pancreat Dis Int, 2018, 17:517-523. [15] 杨金凤, 张秉强. 经颈静脉肝内门体分流术后肝性脑病诊治进展. 中华肝脏病杂志, 2016, 24:545-548. |